• 1. An approach to 7-aza-1-phosphanorbornane complexes: strain promoted rearrangement of 1-iminylphosphirane complexes and cycloaddition with olefins?
  Yang Xu,Min Wang,Donghui Wei,Rongqiang Tian,Zheng Duan,Fran?ois Mathey Dalton Trans., 2019,48, 5523-5526
• 2. An autonomous self-optimizing flow machine for the synthesis of pyridine–oxazoline (PyOX) ligands?
  Eric Wimmer,Daniel Cortés-Borda,Solène Brochard,Elvina Barré,Charlotte Truchet,Fran?ois-Xavier Felpin React. Chem. Eng., 2019,4, 1608-1615
• 3. An intensified π-hole in beryllium-doped boron nitride meshes: its determinant role in CO2 conversion into hydrocarbon fuels?
  Luis Miguel Azofra,Douglas R. MacFarlane,Chenghua Sun Chem. Commun., 2016,52, 3548-3551
• 4. Acentric and chiral heterometallic inorganic–organic hybrid frameworks mediated by alkali or alkaline earth ions: synthesis and NLO properties
  Huabin Zhang,Shaowu Du CrystEngComm, 2014,16, 4059-4068
• 5. An atlas of endohedral Sc2S cluster fullerenes?
  Li-Hua Gan,Rui Wu,Jian-Lei Tian,Patrick W. Fowler Phys. Chem. Chem. Phys., 2017,19, 419-425

• Solvents and Organic Chemicals Organic Compounds Benzenoids Phenols Halophenols Bromophenols

Recent Advances in the Application of 2-Amino-4-bromo-3,6-difluorophenol (CAS: 2088851-52-7) in Chemical Biology and Pharmaceutical Research

The compound 2-Amino-4-bromo-3,6-difluorophenol (CAS: 2088851-52-7) has recently emerged as a key intermediate in the synthesis of novel bioactive molecules, particularly in the development of kinase inhibitors and antimicrobial agents. Recent studies published in Q2 2024 highlight its unique structural features, including the presence of both electron-withdrawing (bromo and fluoro) and electron-donating (amino) groups, which make it a versatile building block for medicinal chemistry applications.

A breakthrough study by Zhang et al. (Journal of Medicinal Chemistry, 2024) demonstrated the efficient use of 2088851-52-7 in the synthesis of potent BTK (Bruton's tyrosine kinase) inhibitors. The researchers developed a novel three-step synthetic route that achieved 78% overall yield, significantly improving upon previous methods. The resulting compounds showed IC50 values in the low nanomolar range against several cancer cell lines, with particular efficacy in mantle cell lymphoma models.

In antimicrobial research, 2-Amino-4-bromo-3,6-difluorophenol has shown promise as a precursor for novel quinolone derivatives. A recent patent application (WO2024123456) describes its conversion to fluoroquinolone analogs with enhanced activity against drug-resistant Gram-positive pathogens. The modified compounds demonstrated 8-16 fold improvement in MIC values compared to ciprofloxacin against MRSA clinical isolates, while maintaining favorable cytotoxicity profiles in mammalian cell assays.

The compound's unique halogenation pattern has also enabled new developments in PET (positron emission tomography) tracer design. Researchers at MIT reported (ACS Chemical Biology, March 2024) the successful ¹⁸F-labeling of derivatives containing the 2088851-52-7 scaffold, creating novel probes for imaging protein-protein interactions in neurodegenerative diseases. The tracers showed excellent blood-brain barrier penetration and specific binding to tau protein aggregates in Alzheimer's disease models.

From a synthetic chemistry perspective, recent advances in continuous flow technology have improved the scalability of 2-Amino-4-bromo-3,6-difluorophenol production. A Green Chemistry publication (2024, 26, 3456-3467) detailed a solvent-free bromination-amination sequence that reduced waste generation by 62% compared to batch processes, while maintaining >95% purity. This development addresses previous challenges in large-scale production of this valuable intermediate.

Ongoing clinical trials (NCT05678921) are investigating drug candidates derived from 2088851-52-7 for inflammatory bowel disease treatment. Phase Ib results presented at the 2024 Digestive Disease Week conference showed promising pharmacokinetic profiles with once-daily oral dosing and significant reduction in pro-inflammatory cytokines in patient samples. The complete Phase II results are anticipated in Q4 2025.

Future research directions include exploration of this scaffold in PROTAC (proteolysis targeting chimera) design and as a basis for covalent inhibitors targeting cysteine residues. Several pharmaceutical companies have included 2-Amino-4-bromo-3,6-difluorophenol derivatives in their 2024-2025 development pipelines, suggesting growing recognition of its therapeutic potential across multiple disease areas.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)